Company: APXIF
Filing Date: 2025-01-22
Form Type: F-4
Source: 0001213900-25-005463
Chunk: 144

Company: APx Acquisition Corp. I
Filing Date: 2025-01-22
Form: F-4
Chunk 144
---
 are seemingly unrelated to the Company’s actual or expected operating performance and financial condition or prospects, prospective investors may have difficulty assessing the rapidly changing value of Company Shares. In addition, investors in Company Shares may experience losses, which may be material, if the price of Company Shares declines after the Closing or if such investors purchase ordinary shares prior to any price decline. A provision of the SPAC Warrant Agreement could cause the downward adjustment of the exercise price for the Company Warrants in connection with the Transaction, which could lead to further dilution for holders of Company Shares. If (i) we issue additional Company Shares or equity -linkedsecurities for capital raising purposes in connection with the closing of the Business Combination at a newly issued price of less than $9.20 per Company Share, (ii) the aggregate gross proceeds from such issuances represent more than 60% of the total equity proceeds, and interest thereon, available for the funding of the Business Combination on the date of the consummation of the Business Combination (net of redemptions), and (iii) the market value of Company Shares is below $9.20 per share, then the exercise price of the Company Warrants will be adjusted (to the nearest cent) to be equal to 115% of the higher of the market value and the newly issued price, and the $18.00 per share redemption trigger prices will be adjusted (to the nearest cent) to be equal to 180% of the higher of the market value and the newly issued price. Prior to the consummation of the Business Combination, we will likely need to raise additional capital. While no definitive documentation has been signed with respect to such additional financing arrangements, such additional financing arrangements may trigger an adjustment of the exercise price of the Company Warrants pursuant to the circumstances described in the preceding paragraph. If the exercise price of the Company Warrants is adjusted downward, it may be more likely that the Company Warrants will be exercised. Any exercise of the Company Warrants would lead to further dilution to holders of Company Shares. The Company may lose its foreign private issuer status, which would then require the Company to comply with the Exchange Act’s domestic reporting regime and cause the Company to incur significant legal, accounting and other expenses. The determination of foreign private issuer status is made annually on the last business day of an issuer’s most recently completed second fiscal quarter. In order to maintain its current status as a foreign private issuer, either (a) more than 50% the outstanding shares of the Company must